CMS Obtained Exclusive License of a Regenerative Collagen Light Medical Aesthetic Product Decellularized Extracellular Matrix Implant

Company News

• The Product, a collagen product with bioactive components, is under China’s registrational clinical trial stage. After validated by clinical trials and approved for marketing, it is expected to provide a medical aesthetic solution that could achieve instant physical filling of skin defects, endogenously induce collagen fiber regeneration, and promote tissue repair, achieving safe, natural, and refined rejuvenation effects.

• The Product will synergize with CMS Skinhealth’s marketed Korean hyaluronic acid product and the regenerative pipeline products, including Poly-L-lactic Acid Microparticle Filler Injection, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection, providing consumers with comprehensive aesthetic solutions.


On June 7, 2024, the subsidiary of China Medical System Holdings Limited (“CMS”), a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement (“the license agreement”) with Shanghai Baiyiyuan Bioengineering Co., Ltd. (“Baiyiyuan Biotech”) for a light medical aesthetic injectable product, Decellularized Extracellular Matrix Implant (the “Product”). In accordance with the license agreement, CMS Skinhealth obtained an exclusive license to promote, market and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan. The term of the exclusive license shall begin from June 7, 2024 to the tenth anniversary after the date of the approval of the registration certificate of Class III medical device of the Product in Mainland China and CMS Skinhealth’s receipt of the first batch of commercialized and marketable products delivered by Baiyiyuan Biotech. Upon the expiration of the aforementioned term, the term of the license agreement will automatically be extended for another period of ten years thereafter if it complies with the terms and conditions of the license agreement.


Decellularized Extracellular Matrix Implant is collagen product with bioactive components, developed for mid-to-deep injection into the facial dermal tissue for the correction of nasolabial fold wrinkles. The Product is a Class III medical device, and currently in China’s registrational clinical trials. Its preclinical research results showed that the Product and its degradation substance had no safety impact on local implant site or entire body system, and the Product showed good filling and regeneration potential.


Through a series of external collaboration and in-house development, CMS Skinhealth has established a competitive light medical aesthetic product portfolio. This collaboration with Baiyiyuan Biotech in Decellularized Extracellular Matrix Implant further upgrades the portfolio of CMS Skinhealth’s regenerative medical aesthetic products, enhancing the company’s competitiveness in light medical aesthetic field. The Product will complement and synergize with marketed Korean hyaluronic acid product, Vmonalisa, and regenerative medical aesthetic pipeline products, including Poly-L-lactic Acid Microparticle Filler Injection, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection, providing consumers with comprehensive aesthetic solutions to meet their personalized and more refined needs for beauty.


The Product “Decellularized Extracellular Matrix Implant”

The core ingredient of the Product, “decellularized extracellular matrix particles”, is derived from porcine small intestinal submucosa, mainly composed of structural proteins Type I and Type III collagen, and contains functional proteins, polysaccharides, cell growth factors and other components [1]. After implantation, the Product is expected to directly supplement collagen and achieve instant physical filling of skin defects; in addition, its structural protein is expected to cooperate with other ingredients to provide a microenvironment to endogenously induce collagen fiber regeneration [2], and promote tissue repair [3]. In this process, the Product can be completely metabolized by the human body. Through multiple mechanisms of action, the Product has the potential to achieve safe, natural, and refined rejuvenation effects.


According to Frost & Sullivan’s forecast, China’s market size for medical aesthetic injectable implants will reach approximately RMB55.8 billion in 2025. Meanwhile, the more refined aesthetic demands expediate the continuous upgrades of medical aesthetic materials towards “safer, more natural, and long-lasting” development direction. As an emerging innovative rejuvenation product, regenerative collagen medical aesthetic injectable implant has promising development potential. CMS Skinhealth will keep up with the development trend of cutting-edge technology, and continuously develop more quality medical aesthetic products with its rich resources and channel advantages, providing professional comprehensive medical aesthetic solutions to consumers.


About Baiyiyuan Biotech

Shanghai Baiyiyuan Bioengineering Co., Ltd. is a high-tech enterprise integrating R&D, production and sales. The company has an independent intellectual property technology system, as well as first-class R&D team with international vision, and a professional and high-quality medical service team. It is committed to providing advanced biological tissue regeneration material products and regenerative medical aesthetic products.

For details, please visit the company’s official website:


About CMS Skinhealth

CMS’s Dermatology and Medical Aesthetic Business adheres to an operation philosophy of “using medical thinking to promote in-depth study of dermatology and aesthetics”, and it adopts the scientific mindset to build the dermatology and medical aesthetic product matrix with dermatology prescription products as the core, achieving full life-cycle skin-health management covering dermatological treatment, skincare and medical aesthetics. As of 31 December 2023, team size of CMS Skinhealth was about 700 people, covering nearly 10,000 hospitals and medical institutions in China.


About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.


CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.


CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.



  1. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4-27. doi:10.1016/j.addr.2015.11.001
  2. Fujii, M.; Tanaka, R. Porcine Small Intestinal Submucosa Alters the Biochemical Properties of Wound Healing: A Narrative Review. Biomedicines 2022, 10, 2213. biomedicines10092213
  3. Luo Y, Bi H, Chen X, Yang K. Regeneration and repair of extracellular matrix and tissue. Tissue engineering research in China. 2021; 25: 1785-90.


CMS Disclaimer and Forward-Looking Statements

Not yet been approved for marketing in China, the Product is currently in China’s registrational clinical trials, and its safety and efficacy need further verification. This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.


This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.